Evaluation of Aliskiren Efficacy by Different Methods of Blood Pressure Measurements

PHASE4TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

December 31, 2011

Conditions
Blood Pressure, High
Interventions
DRUG

Aliskiren

150 mg during the first two weeks , 300 mg for another 10 weeks

Trial Locations (1)

Unknown

Clalit health services, Herzliya

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Meir Medical Center

OTHER